首页> 美国卫生研究院文献>Pharmaceutics >Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
【2h】

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

机译:具有叶酸和生物素的单对双靶向纳米粒子用于抗癌药物递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.
机译:癌症是全世界死亡的主要原因之一,其治疗仍然非常具有挑战性。癌症治疗的有效性显着取决于药物的肿瘤特异性递送。已经开发出纳米粒子药物递送系统以避免常规化疗的副作用。然而,根据最近的建议,未来的纳米医生应主要关注基于配体 - 受体识别的纳米载体的活性靶向,这可能表现出比人类癌症治疗中的被动靶向更好的疗效。然而,由于肿瘤微环境的复杂性,单配体纳米丝胺的功效仍然有限。因此,NPS朝向额外的功能改善,例如pH敏感性(高级单目标NPS)。此外,开发了在同一药物递送系统上含有两种不同类型靶向剂的双靶向纳米颗粒。先进的单靶NPS和双靶向纳米载体存在与细胞选择性,细胞摄取和细胞毒性相关的优异性质,朝向癌细胞,而不是常规药物,非靶向系统和单目标系统而无需额外的功能。叶酸和生物素用于靶向癌症化疗的靶向配体,因为它们是可用的,廉价,无毒,非免疫性和易于修饰的。这些配体用于两者和双目标系统,尽管后者仍然是一种新颖的方法。本综述介绍了近期靶向纳米粒子的抗癌药物递送的近期成就。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号